Veterinary CRO And CDMO Market Size & Share, By Animal Type (Companion, Livestock), Service Type (Discovery, Development), Application - Growth Trends, Regional Insights (U.S., Japan, South Korea, UK, Germany), Competitive Positioning, Global Forecast Report 2025-2034

市場の見通し:

Veterinary CRO & CDMO Market size is predicted to reach USD 15.74 billion by 2034, up from USD 6.77 billion in 2024, reflecting a CAGR of over 8.8% during the forecast period from 2025 to 2034. The industry revenue for 2025 is projected to be USD 7.31 billion.

• Base Year Value (2024): USD 6.77 billion
• CAGR (2025-2034): 8.8%
• Forecast Year Value (2034): USD 15.74 billion
• Historical Data Period: 2021-2034
• Largest Region: North America
• Forecast Period: 2025-2034

市場動向:

Growth Drivers & Opportunities

The Veterinary CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organizations) market is witnessing significant growth, driven by an increasing demand for veterinary research and the rising importance of animal health awareness. As pet ownership continues to rise globally, there is a growing need for innovative veterinary products, including medications and vaccines, to ensure the health and well-being of animals. This surge in demand fosters an environment ripe for both CROs and CDMOs, as they provide essential services that support clinical trials, regulatory compliance, and product development.

Another key growth driver in this market is the increasing investment in animal health research and development. Pharmaceutical companies are allocating more resources towards R&D activities, which is subsequently benefiting CROs and CDMOs. These organizations play a vital role in helping companies navigate through the complex regulatory landscape, allowing for faster and more efficient product development timelines. Additionally, the trend towards outsourcing various stages of drug development is escalating, as companies seek to improve operational efficiency and manage costs, further propelling the growth of veterinary CROs and CDMOs.

Moreover, advancements in technology are presenting new opportunities within the market. Innovations such as telemedicine, wearable health monitoring devices for animals, and advanced data analytics are transforming the way veterinary care is delivered and monitored. CROs and CDMOs can leverage these emerging technologies to enhance their service offerings, streamline clinical processes, and ultimately improve the outcomes of veterinary products. Collaborations between veterinary organizations and tech companies are becoming more common, creating synergies that can accelerate the development of new therapies.

Industry Restraints

Despite its promising growth trajectory, the veterinary CRO and CDMO market faces several challenges that could hinder its expansion. One of the primary restraints is the strict regulatory environment governing animal health products. Navigating through the intricate maze of regulations can be time-consuming and costly for CROs and CDMOs, as they must ensure compliance with various national and international standards. This complexity can deter potential new entrants into the market and slow down the overall pace of innovation.

Additionally, the veterinary market is characterized by a relatively small client base compared to the human healthcare sector. This smaller market can limit the scale and financial resources available to CROs and CDMOs. Furthermore, the reliance on a limited number of large pharmaceutical companies can create vulnerabilities, as shifts in their business strategies or priorities may directly impact the demand for contracting organizations. Economic fluctuations can also affect funding for veterinary research, potentially slowing down investment in new projects.

Moreover, labor shortages and the need for skilled professionals in veterinary medicine and research fields pose another significant challenge. The growing demand for veterinary CROs and CDMOs may not be met due to issues related to workforce availability and training. This gap can restrict the ability of these organizations to respond swiftly to the needs of the market, thereby affecting their sustainability and growth prospects. As the industry evolves, addressing these workforce-related challenges will be crucial for maintaining the momentum of growth in the veterinary CRO and CDMO sectors.

地域別予報:

North America

The North American Veterinary CRO & CDMO market is predominantly driven by the advanced healthcare infrastructure and significant investment in research and development. The United States stands out as the largest market within this region, fueled by a strong presence of both established and emerging veterinary pharmaceutical companies. In particular, states with major biotech clusters, such as California and Massachusetts, are expected to show substantial growth. Canada is also witnessing an increased focus on veterinary services and related research, with ongoing support from government initiatives aimed at improving animal healthcare. Both countries benefit from a high level of consumer awareness regarding pet health, driving demand for innovative veterinary services and products.

Asia Pacific

Asia Pacific is emerging as a dynamic region for the Veterinary CRO & CDMO market, with countries like China and Japan leading the charge. China, with its rapidly growing pet ownership and burgeoning veterinary sector, is expected to exhibit the most significant growth in the coming years. The country’s focus on improvements in livestock health and food safety is boosting the demand for veterinary CROs and CDMOs. Japan maintains a robust market due to its advanced technology in healthcare and a strong regulatory framework, supporting high-quality services and product development. South Korea is also gaining traction, as the government's emphasis on animal welfare and healthcare fuels market expansion.

Europe

In Europe, the Veterinary CRO & CDMO market is characterized by a strong regulatory environment and an established veterinary infrastructure. The United Kingdom is a key player, thanks to its leading veterinary research institutions and a high demand for innovative veterinary medicines associated with increasing pet ownership and livestock management. Germany follows closely, with a well-developed pharmaceutical industry that is investing heavily in the veterinary sector. France is also noteworthy, offering a range of services and products that cater to both companion and farm animals. The overall European market is poised for gradual growth, driven by increased awareness regarding animal health and welfare across the region, particularly as pet ownership continues to rise.

セグメンテーション分析:

In terms of segmentation, the global Veterinary CRO & CDMO market is analyzed on the basis of Animal Type, Service Type, Application.

Animal Type

The Veterinary Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) market is significantly influenced by the animal type segment, which primarily includes companion animals, livestock, and other animals. The companion animal sector, encompassing pets like dogs and cats, demonstrates robust growth driven by increasing pet ownership and heightened awareness regarding animal health. This segment is expected to capture a large market size as pet owners prioritize advanced veterinary care and preventive treatments. The livestock sector, though traditionally slower-growing, is witnessing increasing investments in animal health products driven by the rise in demand for meat and dairy, enhancing its overall growth potential. Moreover, the small but notable segment of other animals, including exotic pets and wildlife, is also projected to grow, albeit at a slower pace, as awareness regarding wildlife health management increases.

Service Type

Within the service type segment, the offerings are categorized into preclinical studies, clinical trials, laboratory services, and consulting services. Preclinical studies hold a significant share due to their foundational role in drug development, catering to both companion and livestock animals while aligning with stringent regulatory requirements. Clinical trials, driven by the necessity for new veterinary medicine approvals, are also expected to show considerable growth, particularly as the demand for innovative treatments rises. Laboratory services, encompassing a range of diagnostic and testing services, continue to gain traction, reflecting an increased focus on preventative care and real-time health monitoring. Consulting services are emerging as a vital component, particularly for companies navigating complex regulatory landscapes, thereby contributing to the overall market expansion.

Application

The application segment of the Veterinary CRO and CDMO market is diversified, spanning therapeutic, diagnostic, and preventive applications. The therapeutic application segment, which includes the development of pharmaceuticals and biologics for treating various animal diseases, is anticipated to account for a significant market share, reflecting ongoing advancements in veterinary medicine. The diagnostic application segment is witnessing rapid growth, fueled by the rising demand for diagnostic tools and tests that enable early disease detection and management in both companion and livestock animals. Preventive applications, focusing on vaccines and preventive health initiatives, are also showing positive trends as pet owners and farmers increasingly prioritize preventive care measures to enhance animal welfare and productivity. This multifaceted growth across applications highlights a holistic approach to animal health management, offering a broad spectrum of opportunities in the veterinary CRO and CDMO landscape.

競争環境:

The Veterinary CRO & CDMO market is characterized by a significant competitive landscape driven by increasing demand for animal health innovations, regulatory complexities, and a growing focus on high-quality research and development. Key players in this market strive to offer comprehensive service portfolios, ranging from preclinical studies to commercial manufacturing, to meet the diverse needs of biopharmaceutical companies and veterinary drug developers. The market is also witnessing a rise in partnerships and collaborations aimed at enhancing service capabilities and expanding geographical reach. The emphasis on tailored solutions, advanced technologies, and the ability to navigate regulatory pathways are critical factors that differentiate companies in this space, creating both opportunities and challenges in a rapidly evolving environment.

Top Market Players

1. Charles River Laboratories International, Inc.

2. Eligo Bioscience

3. WuXi AppTec

4. Labcorp Drug Development

5. Covance Inc.

6. Parexel International Corporation

7. Celerion

8. KCR

9. ICON plc

10. Syneos Health, Inc.